

Ivivi Research

Roma³™ and Torino II™ Use

Roma³™ and Torino II™ are noninvasive, nondrug anti-inflammatory products offered by Ivivi Health Sciences, which provide pulsed electromagnetic field (PEMF) therapy. They are FDA cleared to treat pain and edema and Medicare has approved them to treat all chronic wounds. The products are easy to use, offer both a durable stationary unit model and a single-patient use, disposable model, and are backed by significant scientific data. Ivivi PEMF therapy is easily incorporated into any treatment regimen. There are no known side effects and no adverse events have been reported as a result of the use of Ivivi PEMF products.



How Ivivi Works

PEMF: Natural anti-inflammatory cascade

Ca ²⁺ + CaM	Ca ²⁺ CaM Ca ²⁺ CaM + eNOS	NO·	Decrease in pain & edema	Release of growth factors	Growth of new blood vessels
Calcium (Ca ²⁺) and calmodulin (CaM) bind together	New molecule catalyzes nitric oxide (NO·) production	NO· causes increased blood flow	The result: decrease in pain and edema		
milliseconds	seconds to minutes			hours to days	hours to days

Ivivi in Post-Surgical Pain

Randomized, controlled trial, post primary breast reduction, an invasive surgery with long incisions and pain. Primary post op concerns are re-establishment of blood supply and pain management.




57% reduction in pain at 1 hour post op, 55% less pain medication, 50% less inflammation
--Rohde, et al. (2008).*




Ivivi in Chronic Wounds

RCT treating Stage III-IV sacral wounds in paraplegic veterans



30 days (single daily treatment, 5 days a week) produced 72% improvement in actives over shams
—Kloth, et al. (1999).*

Ivivi in Edema




Standard animal model for assessing anti-inflammatories


61% less edema in the treated group vs. sham group at 8 hours

—Johnson, et al. (2008).*

Peripheral Angiogenesis



Sham-treated arterial loop



Ivivi treated arterial loop

Traditional animal flap model using tail artery. Treated 30 minutes BID. Treated group showed average of 500% increase in growth of new blood vessels. Almost 100% of untreated flaps died. Nearly 100% of treated flaps survived.

—Roland, et al. (2000) and Weber, et al. (2004).*

*Full citations available upon request.